Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)

Interested in the high-growth prospects of the healthcare industry? If so, we ran a list just for you.

We began by screening the medical devices industry for high-growth stocks, with 5-year projected EPS growth above 15%.

We then screened for stocks with strong sales trends by comparing growth in revenue to growth in inventory over the last year. We screened for stocks with positive sales trends, with faster growth in revenue than inventory over the last year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered an encouraging sign.

To screen for strengthening liquidity, we also only focused on those companies with inventory decreasing as a percent of current assets.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall. More investing ideas on Kapitall Wire.

Do you think these companies will meet their high-growth expectations? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. Winner Medical Group Inc. (WWIN): Engages in the research, development, manufacture, and marketing of cotton-base medical dressings and medical disposables. Market cap at $102.35M, most recent closing price at $4.20. 5-year projected EPS growth at 23.00%. Revenue grew by 24.35% during the most recent quarter ($41.31M vs. $33.22M y/y). Inventory grew by -1.17% during the same time period ($26.18M vs. $26.49M y/y). Inventory, as a percentage of current assets, decreased from 38.82% to 31.74% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

2. Nxstage Medical, Inc. (NXTM): Engages in the development, manufacture, and marketing of products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures in the United States. Market cap at $871.51M, most recent closing price at $15.51. 5-year projected EPS growth at 20.00%. Revenue grew by 12.64% during the most recent quarter ($56.95M vs. $50.56M y/y). Inventory grew by -4.79% during the same time period ($34.95M vs. $36.71M y/y). Inventory, as a percentage of current assets, decreased from 23.87% to 22.25% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

3. ResMed Inc. (RMD): Engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Market cap at $4.55B, most recent closing price at $31.86. 5-year projected EPS growth at 15.77%. Revenue grew by 11.43% during the most recent quarter ($349.07M vs. $313.26M y/y). Inventory grew by -10.49% during the same time period ($183.49M vs. $205M y/y). Inventory, as a percentage of current assets, decreased from 17.05% to 13.84% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

4. Tornier N.V. (TRNX): Operates as a medical device company that designs, manufactures, and markets devices for joint replacement and soft tissue repair that enable surgical specialists to improve patients' lives by restoring motion and physical vitality. Market cap at $852.91M, most recent closing price at $21.56. 5-year projected EPS growth at 20.00%. Revenue grew by 7.23% during the most recent quarter ($74.46M vs. $69.44M y/y). Inventory grew by -0.77% during the same time period ($79.79M vs. $80.41M y/y). Inventory, as a percentage of current assets, decreased from 37.35% to 36.14% during the most recent quarter (comparing 13 weeks ending 2012-04-01 to 13 weeks ending 2011-04-03).

5. Orthofix International N.V. (OFIX): Designs, develops, manufactures, markets, and distributes medical equipment used principally by musculoskeletal medical specialists for orthopedic applications. Market cap at $789.66M, most recent closing price at $42.16. 5-year projected EPS growth at 15.33%. Revenue grew by 2.42% during the most recent quarter ($119.49M vs. $116.67M y/y). Inventory grew by -19.96% during the same time period ($78.42M vs. $97.98M y/y). Inventory, as a percentage of current assets, decreased from 28.31% to 19.78% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.